Testing plixorafenib in people whose cancer has a BRAF gene change
Original title: A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called plixorafenib in people whose cancer has a change in a gene called BRAF.
Who this trial is for. This trial is for people with cancer that has a BRAF change, either BRAF V600E or a BRAF fusion. That includes solid tumors that have grown into nearby areas or spread, and brain or spinal cord tumors that have come back or are getting worse. It also includes some rare cancers with a BRAF V600E change, such as anaplastic thyroid, ovarian, and bile duct cancer.
Where it stands. The trial is looking at how well plixorafenib works and how safe it is. Those answers are not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: For now, this is a study, not care your own doctor can give you. If your tumor has a BRAF change, you could ask your care team whether a trial like this is worth looking into. They can explain what it would involve for you.
What it doesn't mean: This does not mean the drug is proven to work. A trial is a test. Joining one is not a guarantee that it will help you. It is not a promise of a cure. It also does not mean you can join. The trial team decides who is a fit.
Source: ClinicalTrials.gov, July 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.